The Food and Drug Administration (FDA) has approved Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...

Concizumab is a tissue factor pathway inhibitor antagonist that enhances factor Xa production during the initiation phase of coagulation. This production improves thrombin generation and clot ...

CBD did not meet primary end point comparing preingestion to postingestion anxiety, but resulted in lower anxiety levels ...

(HealthDay News) — Light-to-moderate consumption of wine, measured through an objective urinary biomarker, is associated with lower cardiovascular disease (CVD) risk in an older Mediterranean ...

(HealthDay News) — The use of influenza testing at hospital emergency department visits increased from 2013 to 2022 in the United States, according to a December data brief published by the National ...

Results from the VENTURE trial showed significant reductions in weight and hunger among younger patients treated with ...

The sBLA submission included results from the randomized, parallel-arm, placebo-controlled and active-controlled trial foresiGHt.

Veligrotug is an investigational monoclonal antibody that inhibits the activity of insulin-like growth factor-1 receptor.

The FDA is recommending an additional clinical trial to confirm glepaglutide’s efficacy and safety at the to-be-marketed dose.

Pyridostigmine bromide 180mg; sust rel scored tabs.

The Food and Drug Administration (FDA) has approved Tryngolza™ (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).

Hydrocodone bitartrate 10mg, chlorpheniramine maleate 8mg; as polistirex; ext–rel caps; contains alcohol. Hydrocodone is a semisynthetic narcotic antitussive and analgesic with multiple actions ...